Other

Taiho Pharmaceutical Company Limited

Senju Pharmaceutical Co., Ltd.

Sagami Chemical Research Center

Hitoshi Ohmori

Takahiro Ogawa

Seishi Kato

Shingo Sekine

Fuminori Tokumochi

Tomoko Tsuji

Suwan Oh

Midori Kobayashi

Atsushi Okumura

Naoki Kanayama

Mihoro Saeki

Mika Yada

Methods are provided for selecting B cells that produce a desired antibody, comprising a step of culturing B cells, which have the properties of cell death being induced under specific conditions and that cell death being suppressed by a signal generated as a result of the binding between an antigen and an antibody expressed on B cell surface (B cell antigen receptor on the B cell surface), with an antigen under conditions in which cell death is induced, and selecting antibody-producing B cells that bind with the antigen as viable cells.

Methods for specifically selecting antibody-producing cells

Isolated cDNAs derived from mRNAs expressed in human cells are provided, as are DNAs and RNAs comprising their nucleotide sequences, and vectors for expressing the cDNAs. The cDNAs encode proteins which have functions similar to known proteins.

Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent

The present invention provides an anti-allergic pharmaceutical composition for ophthalmic topical administration comprising an IgE antibody production inhibitor as an active ingredient. The present invention also provides a process for producing an anti-allergic pharmaceutical composition for ophthalmic topical administration, which comprises mixing an IgE antibody production inhibitor with a pharmaceutically acceptable carrier, excipient or diluent.

Anti-allergic pharmaceutical composition for ophthalmic topical

Growing community of inventors

Okayama, Japan

Hitoshi Ohmori